Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Enrollment: Drug Plans Have 11.6 Mil. Beneficiaries To Date, CMS Says

Executive Summary

Roughly 11.6 mil. Medicare beneficiaries were enrolled in either stand-alone or Medicare Advantage Part D drug plans as of Dec. 13, numbers released by the Centers for Medicare & Medicaid Services show

You may also be interested in...



Stand-Alone Drug Plan Enrollment Jumps As CMS Works To Resolve Glitches

Enrollment in Part D stand-alone and Medicare Advantage (MA) drug plans topped 14 mil. in the two months after beneficiaries could start signing up for the program. Yet mishaps in processing prescriptions persist for the largest group of those enrollees - Medicare/Medicaid dual eligibles - even as CMS continues to tweak data systems and work with plans to correct the problems

Stand-Alone Drug Plan Enrollment Jumps As CMS Works To Resolve Glitches

Enrollment in Part D stand-alone and Medicare Advantage (MA) drug plans topped 14 mil. in the two months after beneficiaries could start signing up for the program. Yet mishaps in processing prescriptions persist for the largest group of those enrollees - Medicare/Medicaid dual eligibles - even as CMS continues to tweak data systems and work with plans to correct the problems

Part D-Day: Pharmacies Fill “Millions” Of Rxs In Opening Days Despite Glitches

Pharmacies filled "millions" of Medicare Part D prescriptions in the first few days of the program, despite numerous problems pharmacists faced in processing claims, CMS said

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel